Heron Therapeutics (NASDAQ:HRTX) has grabbed attention from the analysts, when it saw a value decrease of -2.78% or -0.4 points in the last trading session to close at $14. A total of 1.27 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 684.87 Million shares, while its relative volume stands at 1.86. Heron Therapeutics (NASDAQ:HRTX) has a market cap of $754.46 Million and the number of outstanding shares have been calculated 53.89 Million.

Shares of Heron Therapeutics (NASDAQ:HRTX) currently have an Average Brokerage Recommendation of 1.13, number of Recs in ABR is 8 while industry rank of the company by ABR is 157 out of 265. Out of the analyst recommendations 2 rate Heron Therapeutics (NASDAQ:HRTX) stock a Buy, 7 rate the stock Outperform, 0 rate Hold, 0 rate Underperform and 0 recommend a Sell.

In order to check on the sell-side rational, we can also take a peek at some technical indicators. Heron Therapeutics (NASDAQ:HRTX)’s price sits -3.21% off from its 50-day moving average of $14.18 and -5.89% away from the stock’s 200-day moving average which is $14.11. Stock’s twelve month price oscillated between $24.00 and $12.21. The stock hit its twelve month high on 08/10/16, and twelve month low on 01/12/17. The Average True Range, a measure of volatility is at 0.69, however its weekly and monthly volatility is 3.77%, 4.68% respectively. The company’s Relative Strength Index which shows price strength currently stands at 45.74.

Heron Therapeutics (NASDAQ:HRTX) as of recent trade, has shown weekly upbeat performance of 1.08% which was maintained at -3.78% in 1-month period. During the past three months the stock gain 1.82%, bringing six months performance to 4.48%. Yearly performance of the stock shows a bearish trend of -22.09% while year-to-date (YTD) performance reflected 6.87% positive outlook.

While taking a glance at financials, we can look at a number of key indicators. Heron Therapeutics (NASDAQ:HRTX) has trailing twelve month Return on Assets of -172.1%, which is key indicator of how profitable a company is relative to its total assets. The company currently has a Return on Equity of -485.3% and a Return on Investment of -540.9%. ROI is a performance measure used to evaluate the efficiency of an investment or to compare the efficiency of a number of different investments.

While having a peek at profitability ratios Heron Therapeutics (NASDAQ:HRTX) has trailing twelve month gross margin at 75.1%, its trailing twelve month operating margin stands at 0% whereas its trailing twelve month net profit margin spots at 0%.

However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0. The company’s forward price to earnings ratio for next fiscal year is 0. Heron Therapeutics (NASDAQ:HRTX)’s price to free cash flow for trailing twelve months is 0. Its beta value stands at 2.04.

The company’s quick ratio for most recent quarter is 4.8 along with current ratio for most recent quarter of 4.9. Total debt to equity ratio of the company for most recent quarter is 0.52 whereas long term debt to equity ratio for most recent quarter is 0.49.

Having a peek at growth estimates of the company, Heron Therapeutics (NASDAQ:HRTX) has current quarter growth estimates of 20.5% however it has 25.8% estimations over growth for the next quarter. During current year the company’s forecasts over growth are 18.2% while for the next year analysts’ growth estimation is 34.9%. Past 5 years growth of the company observed at -43.36%, and for the next five years the analysts that follow the company are expecting its growth at 26.7%.